Do analysts prefer LIMN or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Liminatus Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings & valuation, LIMN or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liminatus Pharma N/A N/A -$10.21M -$0.44 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is LIMN or ATXI more profitable?

Liminatus Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Liminatus Pharma N/A N/A -299.79% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts prefer ATXI or RDHL?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Redhill Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is ATXI or RDHL more profitable?

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% Redhill Biopharma N/A N/A N/A

Do analysts recommend RNAZ or ATXI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger valuation and earnings, RNAZ or ATXI?

Avenue Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$50.33 N/A Avenue Therapeutics N/A N/A -$10.38M -$0.53 N/A

Is RNAZ or ATXI more profitable?

Avenue Therapeutics' return on equity of -471.57% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -50.36% Avenue Therapeutics N/A -471.57% -296.50%

Do analysts rate ATXI or GOVX?

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 GeoVax Labs 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Is ATXI or GOVX more profitable?

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity. Company Net Margins Return on Equity Return on Assets Avenue Therapeutics N/A -471.57% -296.50% GeoVax Labs N/A -709.52% -399.33%

Do analysts rate ATXI or SXTP?

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Avenue Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 60 Degrees Pharmaceuticals 1 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Avenue Therapeutics (ATXI) Competitors

$0.30 0.00 (0.00%)

As of 07/2/2026 02:12 PM Eastern

Compare

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

Should you buy Avenue Therapeutics stock or one of its competitors? MarketBeat compares Avenue Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Avenue Therapeutics include Liminatus Pharma (LIMN), Redhill Biopharma (RDHL), TransCode Therapeutics (RNAZ), GeoVax Labs (GOVX), and 60 Degrees Pharmaceuticals (SXTP). These companies are all part of the "pharmaceutical products" industry.

How does Avenue Therapeutics compare to Liminatus Pharma?

Liminatus Pharma (NASDAQ:LIMN) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations.

Avenue Therapeutics is trading at a lower price-to-earnings ratio than Liminatus Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liminatus Pharma	N/A	N/A	-$10.21M	-$0.44	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

In the previous week, Liminatus Pharma had 3 more articles in the media than Avenue Therapeutics. MarketBeat recorded 3 mentions for Liminatus Pharma and 0 mentions for Avenue Therapeutics. Liminatus Pharma's average media sentiment score of 0.64 beat Avenue Therapeutics' score of 0.00 indicating that Liminatus Pharma is being referred to more favorably in the media.

Company	Overall Sentiment
Liminatus Pharma	Positive
Avenue Therapeutics	Neutral

Liminatus Pharma has a beta of 5.62, suggesting that its share price is 462% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, suggesting that its share price is 117% less volatile than the broader market.

Liminatus Pharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liminatus Pharma	N/A	N/A	-299.79%
Avenue Therapeutics	N/A	-471.57%	-296.50%

17.3% of Avenue Therapeutics shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liminatus Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Liminatus Pharma beats Avenue Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Avenue Therapeutics compare to Redhill Biopharma?

Avenue Therapeutics (NASDAQ:ATXI) and Redhill Biopharma (NASDAQ:RDHL) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation, risk and media sentiment.

Redhill Biopharma has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than Redhill Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
Redhill Biopharma	$290K	14.54	-$430K	$1.05 thousand	0.00

Avenue Therapeutics has a beta of -0.17, indicating that its share price is 117% less volatile than the broader market. Comparatively, Redhill Biopharma has a beta of 4.98, indicating that its share price is 398% more volatile than the broader market.

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 7.2% of Redhill Biopharma shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 6.8% of Redhill Biopharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Avenue Therapeutics' average media sentiment score of 0.00 equaled Redhill Biopharma'saverage media sentiment score.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
Redhill Biopharma	Neutral

Redhill Biopharma's return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
Redhill Biopharma	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Redhill Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Redhill Biopharma beats Avenue Therapeutics on 7 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to TransCode Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Avenue Therapeutics (NASDAQ:ATXI) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

17.3% of Avenue Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by company insiders. Comparatively, 8.6% of Avenue Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, TransCode Therapeutics had 1 more articles in the media than Avenue Therapeutics. MarketBeat recorded 1 mentions for TransCode Therapeutics and 0 mentions for Avenue Therapeutics. TransCode Therapeutics' average media sentiment score of 0.00 equaled Avenue Therapeutics'average media sentiment score.

Company	Overall Sentiment
TransCode Therapeutics	Neutral
Avenue Therapeutics	Neutral

TransCode Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the broader market. Comparatively, Avenue Therapeutics has a beta of -0.17, meaning that its stock price is 117% less volatile than the broader market.

Avenue Therapeutics' return on equity of -471.57% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-50.36%
Avenue Therapeutics	N/A	-471.57%	-296.50%

Avenue Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$50.33	N/A
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Avenue Therapeutics beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

How does Avenue Therapeutics compare to GeoVax Labs?

Avenue Therapeutics (NASDAQ:ATXI) and GeoVax Labs (NASDAQ:GOVX) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation, institutional ownership and media sentiment.

Avenue Therapeutics has higher earnings, but lower revenue than GeoVax Labs. Avenue Therapeutics is trading at a lower price-to-earnings ratio than GeoVax Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
GeoVax Labs	$2.49M	1.66	-$21.47M	-$19.12	N/A

Avenue Therapeutics has a beta of -0.17, meaning that its share price is 117% less volatile than the broader market. Comparatively, GeoVax Labs has a beta of 3.68, meaning that its share price is 268% more volatile than the broader market.

In the previous week, GeoVax Labs had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for GeoVax Labs and 0 mentions for Avenue Therapeutics. GeoVax Labs' average media sentiment score of 0.49 beat Avenue Therapeutics' score of 0.00 indicating that GeoVax Labs is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
GeoVax Labs	Neutral

GeoVax Labs has a consensus target price of $150.00, suggesting a potential upside of 12,505.04%. Given GeoVax Labs' stronger consensus rating and higher probable upside, analysts plainly believe GeoVax Labs is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
GeoVax Labs	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Avenue Therapeutics' return on equity of -471.57% beat GeoVax Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
GeoVax Labs	N/A	-709.52%	-399.33%

17.3% of Avenue Therapeutics shares are held by institutional investors. Comparatively, 6.1% of GeoVax Labs shares are held by institutional investors. 8.6% of Avenue Therapeutics shares are held by insiders. Comparatively, 0.7% of GeoVax Labs shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Avenue Therapeutics beats GeoVax Labs on 7 of the 13 factors compared between the two stocks.

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Avenue Therapeutics (NASDAQ:ATXI) and 60 Degrees Pharmaceuticals (NASDAQ:SXTP) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation and institutional ownership.

60 Degrees Pharmaceuticals has higher revenue and earnings than Avenue Therapeutics. Avenue Therapeutics is trading at a lower price-to-earnings ratio than 60 Degrees Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avenue Therapeutics	N/A	N/A	-$10.38M	-$0.53	N/A
60 Degrees Pharmaceuticals	$1.41M	3.23	-$7.36M	-$8.92	N/A

60 Degrees Pharmaceuticals has a consensus target price of $13.85, suggesting a potential upside of 709.94%. Given 60 Degrees Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe 60 Degrees Pharmaceuticals is more favorable than Avenue Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avenue Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
60 Degrees Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

17.3% of Avenue Therapeutics shares are owned by institutional investors. Comparatively, 8.0% of 60 Degrees Pharmaceuticals shares are owned by institutional investors. 8.6% of Avenue Therapeutics shares are owned by insiders. Comparatively, 1.7% of 60 Degrees Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, 60 Degrees Pharmaceuticals had 2 more articles in the media than Avenue Therapeutics. MarketBeat recorded 2 mentions for 60 Degrees Pharmaceuticals and 0 mentions for Avenue Therapeutics. 60 Degrees Pharmaceuticals' average media sentiment score of 0.75 beat Avenue Therapeutics' score of 0.00 indicating that 60 Degrees Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Avenue Therapeutics	Neutral
60 Degrees Pharmaceuticals	Positive

Avenue Therapeutics has a beta of -0.17, suggesting that its stock price is 117% less volatile than the broader market. Comparatively, 60 Degrees Pharmaceuticals has a beta of 2.47, suggesting that its stock price is 147% more volatile than the broader market.

Avenue Therapeutics has a net margin of 0.00% compared to 60 Degrees Pharmaceuticals' net margin of -574.91%. 60 Degrees Pharmaceuticals' return on equity of 0.00% beat Avenue Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avenue Therapeutics	N/A	-471.57%	-296.50%
60 Degrees Pharmaceuticals	-574.91%	N/A	-131.48%

Summary

60 Degrees Pharmaceuticals beats Avenue Therapeutics on 10 of the 15 factors compared between the two stocks.

Get Avenue Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATXI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATXI vs. The Competition

Export

Metric	Avenue Therapeutics	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.01M	$791.45M	$7.16B	$12.48B
Dividend Yield	N/A	4.84%	2.66%	6.52%
P/E Ratio	0.02	1.66	28.02	24.70
Price / Sales	N/A	127.11	540.37	99.49
Price / Cash	N/A	20.06	49.26	57.09
Price / Book	0.16	8.17	10.96	6.46
Net Income	-$10.38M	-$3.71M	$3.57B	$337.01M
7 Day Performance	8.93%	2.59%	2.12%	1.69%
1 Month Performance	-13.48%	4.41%	5.25%	3.81%
1 Year Performance	-10.27%	49.43%	33.29%	23.90%

Avenue Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATXI Avenue Therapeutics	N/A	$0.31 flat	N/A	-10.3%	$1.01M	N/A	0.02	4	Gap Down
LIMN Liminatus Pharma	1.0707 of 5 stars	$0.10 -1.1%	N/A	-98.4%	$4.53M	N/A	N/A	N/A	Gap Up
RDHL Redhill Biopharma	1.3312 of 5 stars	$0.87 -4.3%	N/A	-59.7%	$4.52M	$290K	0.00	210	Short Interest Decrease Gap Down
RNAZ TransCode Therapeutics	0.1162 of 5 stars	$4.72 -3.5%	N/A	+7.1%	$4.51M	N/A	N/A	9	News Coverage Short Interest Increase
GOVX GeoVax Labs	2.6784 of 5 stars	$1.29 -6.5%	$150.00 +11,527.9%	-90.1%	$4.48M	$2.49M	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATXI) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

How does Avenue Therapeutics compare to Liminatus Pharma?

Summary

How does Avenue Therapeutics compare to Redhill Biopharma?

Summary

How does Avenue Therapeutics compare to TransCode Therapeutics?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Summary

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Avenue Therapeutics (ATXI) Competitors

ATXI vs. LIMN, RDHL, RNAZ, GOVX, and SXTP

How does Avenue Therapeutics compare to Liminatus Pharma?

Which has stronger earnings & valuation, LIMN or ATXI?

Does the media refer more to LIMN or ATXI?

Which has more risk & volatility, LIMN or ATXI?

Is LIMN or ATXI more profitable?

Do insiders and institutionals believe in LIMN or ATXI?

Do analysts prefer LIMN or ATXI?

Summary

How does Avenue Therapeutics compare to Redhill Biopharma?

Which has higher valuation & earnings, ATXI or RDHL?

Which has more volatility & risk, ATXI or RDHL?

Do institutionals & insiders have more ownership in ATXI or RDHL?

Does the media favor ATXI or RDHL?

Is ATXI or RDHL more profitable?

Do analysts prefer ATXI or RDHL?

Summary

How does Avenue Therapeutics compare to TransCode Therapeutics?

Do insiders & institutionals believe in RNAZ or ATXI?

Does the media favor RNAZ or ATXI?

Which has more volatility and risk, RNAZ or ATXI?

Is RNAZ or ATXI more profitable?

Which has stronger valuation and earnings, RNAZ or ATXI?

Do analysts recommend RNAZ or ATXI?

Summary

How does Avenue Therapeutics compare to GeoVax Labs?

Which has stronger earnings and valuation, ATXI or GOVX?

Which has more volatility and risk, ATXI or GOVX?

Does the media favor ATXI or GOVX?

Do analysts rate ATXI or GOVX?

Is ATXI or GOVX more profitable?

Do insiders and institutionals hold more shares of ATXI or GOVX?

Summary

How does Avenue Therapeutics compare to 60 Degrees Pharmaceuticals?

Which has higher valuation & earnings, ATXI or SXTP?

Do analysts rate ATXI or SXTP?

Do institutionals & insiders hold more shares of ATXI or SXTP?

Does the media prefer ATXI or SXTP?

Which has more volatility and risk, ATXI or SXTP?

Is ATXI or SXTP more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATXI vs. The Competition

Avenue Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools